Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vor Biopharma Inc.

1.93
-0.0700-3.50%
Post-market: 1.930.00000.00%16:29 EDT
Volume:4.78M
Turnover:9.24M
Market Cap:244.50M
PE:-0.11
High:2.01
Open:1.98
Low:1.90
Close:2.00
52wk High:3.29
52wk Low:0.1311
Shares:126.68M
Float Shares:47.62M
Volume Ratio:1.13
T/O Rate:10.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.1330
EPS(LYR):-1.7017
ROE:-125.43%
ROA:-121.29%
PB:-0.16
PE(LYR):-1.13

Loading ...

Vor Biopharma Inc. Appoints Adi Osovsky as General Counsel to Support Strategic Growth

Reuters
·
Sep 02

Vor Bio Appoints Adi Osovsky, S.j.d. as General Counsel

THOMSON REUTERS
·
Sep 02

Major Shareholder Sells Over a Million Shares of Vor Biopharma!

TIPRANKS
·
Aug 30

Beneficial Owner Reprogrammed Interchange LLC Reports Disposal of Common Shares of Vor Biopharma Inc

Reuters
·
Aug 28

Vor Biopharma Appoints Sarah Reed to Board

TIPRANKS
·
Aug 28

Vor Biopharma Inc. Announces Board Resignations and Appointment of Sarah Reed as New Director

Reuters
·
Aug 28

Vor Biopharma Files Prospectus for $119.7M Stock Sale

TIPRANKS
·
Aug 27

Vor Bio Says Telitacicept Achieves Primary Endpoint in Phase 3 Kidney Disease Study

MT Newswires Live
·
Aug 27

Vor Biopharma Inc. Conducted Special Stockholder Meeting

Reuters
·
Aug 27

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Iga Nephropathy

THOMSON REUTERS
·
Aug 27

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Aug 19

Vor Biopharma Announces New Stock Option and RSU Grants as Inducement for New Employees

Reuters
·
Aug 19

Vor Biopharma options imply 7.4% move in share price post-earnings

TIPRANKS
·
Aug 14

Sector Update: Health Care Stocks Gain Wednesday Afternoon

MT Newswires Live
·
Aug 14

BUZZ-U.S. STOCKS ON THE MOVE-Lumentum Holdings, ImmunityBio, V2X

Reuters
·
Aug 13

Vor Biopharma Shares up 25% Premarket After Late-Stage Data for Immune Disorder Drug

THOMSON REUTERS
·
Aug 13

Vor Biopharma Shares Jump After Phase 3 Telitacicept Study Achieves Primary Endpoint

MT Newswires Live
·
Aug 13

BUZZ-Vor Bio jumps after late-stage data for immune disorder drug

Reuters
·
Aug 13

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary SjÖGren's Disease With Telitacicept, a Dual Baff/April Inhibitor

THOMSON REUTERS
·
Aug 13

Vor Biopharma Inc - Evaluating Timing of Global Phase 3 Clinical Study in Primary SjÖGren's Disease

THOMSON REUTERS
·
Aug 13